Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Immune checkpoint inhibitors (ICIs) are an important advancement in the field of cancer treatment, significantly improving the survival of patients with a series of advanced malignancies, like melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), a...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/18/10948 |
| _version_ | 1797486998439591936 |
|---|---|
| author | Angela Cozma Nicolae Dan Sporis Andrada Luciana Lazar Andrei Buruiana Andreea Maria Ganea Toma Vlad Malinescu Bianca Mihaela Berechet Adriana Fodor Adela Viviana Sitar-Taut Vasile Calin Vlad Vasile Negrean Olga Hilda Orasan |
| author_facet | Angela Cozma Nicolae Dan Sporis Andrada Luciana Lazar Andrei Buruiana Andreea Maria Ganea Toma Vlad Malinescu Bianca Mihaela Berechet Adriana Fodor Adela Viviana Sitar-Taut Vasile Calin Vlad Vasile Negrean Olga Hilda Orasan |
| author_sort | Angela Cozma |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) are an important advancement in the field of cancer treatment, significantly improving the survival of patients with a series of advanced malignancies, like melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and Hodgkin lymphoma. ICIs act upon T lymphocytes and antigen-presenting cells, targeting programmed cell death protein 1 (PD1), programmed cell death protein ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4), breaking the immune tolerance of the T cells against malignant cells and enhancing the body’s own immune response. A variety of cardiac-adverse effects are associated with ICI-based treatment, including pericarditis, arrhythmias, cardiomyopathy, and acute coronary syndrome, with myocarditis being the most studied due to its often-unexpected onset and severity. Overall, Myocarditis is rare but presents an immune-related adverse event (irAE) that has a high fatality rate. Considering the rising number of oncological patients treated with ICIs and the severity of their potential adverse effects, a good understanding and continuous investigation of cardiac irAEs is of the utmost importance. This systematic review aimed to revise recent publications (between 2016–2022) on ICI-induced cardiac toxicities and highlight the therapeutical approach and evolution in the selected cases. |
| first_indexed | 2024-03-09T23:42:21Z |
| format | Article |
| id | doaj.art-e386d4b65ee9465695013962067b77d8 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T23:42:21Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-e386d4b65ee9465695013962067b77d82023-11-23T16:51:07ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-09-0123181094810.3390/ijms231810948Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic ReviewAngela Cozma0Nicolae Dan Sporis1Andrada Luciana Lazar2Andrei Buruiana3Andreea Maria Ganea4Toma Vlad Malinescu5Bianca Mihaela Berechet6Adriana Fodor7Adela Viviana Sitar-Taut8Vasile Calin Vlad9Vasile Negrean10Olga Hilda Orasan11Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Medical Oncology, Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, RomaniaDepartment of Dermatology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Medical Oncology, Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, RomaniaDepartment of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaClinical Centre of Diabetes, Nutrition and Metabolic Disease, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaImmune checkpoint inhibitors (ICIs) are an important advancement in the field of cancer treatment, significantly improving the survival of patients with a series of advanced malignancies, like melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and Hodgkin lymphoma. ICIs act upon T lymphocytes and antigen-presenting cells, targeting programmed cell death protein 1 (PD1), programmed cell death protein ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4), breaking the immune tolerance of the T cells against malignant cells and enhancing the body’s own immune response. A variety of cardiac-adverse effects are associated with ICI-based treatment, including pericarditis, arrhythmias, cardiomyopathy, and acute coronary syndrome, with myocarditis being the most studied due to its often-unexpected onset and severity. Overall, Myocarditis is rare but presents an immune-related adverse event (irAE) that has a high fatality rate. Considering the rising number of oncological patients treated with ICIs and the severity of their potential adverse effects, a good understanding and continuous investigation of cardiac irAEs is of the utmost importance. This systematic review aimed to revise recent publications (between 2016–2022) on ICI-induced cardiac toxicities and highlight the therapeutical approach and evolution in the selected cases.https://www.mdpi.com/1422-0067/23/18/10948immune checkpoint inhibitorsmyocarditispericarditisarrythmiacardiomyopathy |
| spellingShingle | Angela Cozma Nicolae Dan Sporis Andrada Luciana Lazar Andrei Buruiana Andreea Maria Ganea Toma Vlad Malinescu Bianca Mihaela Berechet Adriana Fodor Adela Viviana Sitar-Taut Vasile Calin Vlad Vasile Negrean Olga Hilda Orasan Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review International Journal of Molecular Sciences immune checkpoint inhibitors myocarditis pericarditis arrythmia cardiomyopathy |
| title | Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review |
| title_full | Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review |
| title_fullStr | Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review |
| title_full_unstemmed | Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review |
| title_short | Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review |
| title_sort | cardiac toxicity associated with immune checkpoint inhibitors a systematic review |
| topic | immune checkpoint inhibitors myocarditis pericarditis arrythmia cardiomyopathy |
| url | https://www.mdpi.com/1422-0067/23/18/10948 |
| work_keys_str_mv | AT angelacozma cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT nicolaedansporis cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT andradalucianalazar cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT andreiburuiana cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT andreeamariaganea cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT tomavladmalinescu cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT biancamihaelaberechet cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT adrianafodor cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT adelavivianasitartaut cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT vasilecalinvlad cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT vasilenegrean cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview AT olgahildaorasan cardiactoxicityassociatedwithimmunecheckpointinhibitorsasystematicreview |